DVAX 11.99 (+1.44%)
US2681582019BiotechnologyBiotechnology

Dynavax Technologies (DVAX) Stock Highlights

11.99 | +1.44%
2024-06-03 01:41:51
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the bodys innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product.

Statistics

Range Today
11.79 12.06
Volume Today 2.93M
Range 1 Year
10.48 15.15
Volume 1 Year 462.68M
Range 3 Year
7.26 21.39
Volume 3 Year 1.63B
Range 10 Year
1.8 32.49
Volume 10 Year 4.75B

Highlights

Market Capitalization 1.57B (small)
Floating Shares 121.27M
Current Price 11.99
Price To Earnings 169
Price To Revenue 4.57
Price To Book 2.54
Earnings Per Share 0.07
Payout Ratio 0%

Performance

Latest +1.44%
1 Month +4.9%
3 Months -5.66%
6 Months -12.16%
1 Year +6.96%
3 Years +44.81%
5 Years +147.73%
10 Years -16.15%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.